Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down – Should You Sell?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $101.35, but opened at $78.62. Sarepta Therapeutics shares last traded at $79.25, with a volume of 2,825,667 shares changing hands.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on SRPT shares. Royal Bank of Canada cut their price objective on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. HC Wainwright restated a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Deutsche Bank Aktiengesellschaft started coverage on shares of Sarepta Therapeutics in a research note on Tuesday, February 11th. They issued a “hold” rating and a $136.00 target price for the company. Scotiabank assumed coverage on Sarepta Therapeutics in a research report on Friday, March 7th. They issued a “sector perform” rating and a $105.00 price objective for the company. Finally, StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $170.23.

Sarepta Therapeutics Trading Down 20.6 %

The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a market capitalization of $7.80 billion, a price-to-earnings ratio of 64.66 and a beta of 0.79. The firm has a fifty day moving average price of $111.20 and a 200-day moving average price of $119.57.

Insider Buying and Selling

In other news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.70% of the stock is currently owned by company insiders.

Institutional Trading of Sarepta Therapeutics

Large investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC lifted its stake in Sarepta Therapeutics by 4.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,699 shares of the biotechnology company’s stock worth $571,000 after purchasing an additional 218 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $244,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Sarepta Therapeutics by 11.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 299,301 shares of the biotechnology company’s stock worth $36,392,000 after buying an additional 31,098 shares in the last quarter. Woodline Partners LP acquired a new position in shares of Sarepta Therapeutics during the 4th quarter worth $5,713,000. Finally, Vestal Point Capital LP bought a new stake in shares of Sarepta Therapeutics during the 4th quarter worth $30,398,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.